TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01347827

Intervention type: DEVICE
Intervention: measurements of brain tissue oxygenation
Description: different monitors((the Hutchinson InSpectra™ StO2 Tissue Oxygenation Monitor) and in cerebral (ForeSight® Cerebral Oximeter and the Somanetics INVOS® Cerebral Oximeter ) and renal tissue (the Somanetics INVOS® Cerebral Oximeter)of brain tissue oxygenation with each other, and assess the correlation between brain tissue oxygenation and oxygenation measurements in renal and muscular tissue, as well as with conventional hemodynamic and metabolic variables, such as central venous oxygen saturation

Intervention type: DEVICE
Intervention: measurements of brain tissue oxygenation
Description: different monitors((the Hutchinson InSpectra™ StO2 Tissue Oxygenation Monitor) and in cerebral (ForeSight® Cerebral Oximeter and the Somanetics INVOS® Cerebral Oximeter ) and renal tissue (the Somanetics INVOS® Cerebral Oximeter) of brain tissue oxygenation with each other, and assess the correlation between brain tissue oxygenation and oxygenation measurements in renal and muscular tissue, as well as with conventional hemodynamic and metabolic variables, such as central venous oxygen saturation
Study: NCT03964142

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation
Description: Integrated cardiac rehabilitation program that includes supervised exercise training\*.~\* Due to the COVID-19 pandemic, supervised physical exercise training had to be conducted telematically (through live guided training sessions conducted online, with the same design, frequency, and dosage of exercise).
Study: NCT03804723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral Prednisone 5mg
Description: patients randomized to this arm will stop prednisone 5 mg
Study: NCT03941535

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin K
Description: Administration of intravenous Vitamin K in doses of 10mg/day, 5mg/day or 2mg/day
Study: NCT01277354

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Processing Therapy
Description: CPT utilizes a combination of a) exposure therapy aimed at extinguishing fear and distress induced by memories and external cues associated with the trauma, and b) cognitive behavioral techniques that address faulty thinking patterns developed to promote a sense of control over possible future traumas, but that instead perpetuate PTSD symptoms. In CPT, exposure to the traumatic memory occurs through writing and reading for periods of time determined by the client and is confined to the week of the 4th and 5th sessions. These sessions are otherwise used to identify stuck-points, i.e., distorted interpretations regarding the trauma and unrealistic beliefs regarding self and others.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Waitlist Placebo
Description: Behavioral ratings are conducted by a blind rater.
Study: NCT03804723

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: oral Prednisone 5mg
Description: patients randomized to this arm will stop prednisone 5 mg
Study: NCT01219179

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sterile water feedings
Description: Control group- no intervention~Prophylactic group will receive sterile water feeds starting at 24 hours of life if/or when their serum sodium value is ≥ 145 mEq/L. The volume of sterile water is 10mls/Kg/day based on birth weight, given via continuous infusion feed.~The feeding will be stopped when the serum sodium value is ≤ 140 mEq/L.~The hypernatremia group will receive sterile water feeds when their serum sodium value is ≥ 150 meq/L. The volume of sterile water is 10 mls/Kg/day based on birth weight,given via continuous infusion feed. The feeding will be stopped when the serum sodium value is ≤ 140 mEq/L.
Study: NCT01806675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-fludeoxyglucose (18F-FDG)
Description: 18F-FDG will be used as the radiotracer for a regular medical care PET/CT or PET/MRI scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FPPRGD2
Description: 18F-FPPRGD2 will be used as the radiotracer for a PET/CT or PET/MRI scan. Participants will be injected with less than 10 mCi of 18F-FPPRGD2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FPPRGD2
Description: 18F-FPPRGD2 will be used as the radiotracer for a PET/CT or PET/MRI scan. Participants will be injected with less than 10 mCi of 18F-FPPRGD2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FPPRGD2
Description: 18F-FPPRGD2 will be used as the radiotracer for a PET/CT or PET/MRI scan. Participants will be injected with less than 10 mCi of 18F-FPPRGD2.
Study: NCT01015170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupropion HCl
Description: 150mg BID for up to 8 weeks + counseling
Study: NCT02160652

Intervention type: PROCEDURE
Intervention: Laparoscopic ureteral re-implantation.
Description: Laparoscopic ureteral re-implantation for the treatment of malignant ureteral obstruction.
Study: NCT03113773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proleukin
Description: Patients will be treated with subcutaneous injections of IL-2 (range 0.3 X 10\^6 - 3.0 X 10\^6 IU) or placebo once daily for five consecutive days during the trial.A maximum dose of 3.0 X 10\^6 IU will be allowed per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proleukin
Description: Patients will be treated with subcutaneous injections of IL-2 (range 0.3 X 10\^6 - 3.0 X 10\^6 IU) or placebo once daily for five consecutive days during the trial.A maximum dose of 3.0 X 10\^6 IU will be allowed per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Injection
Description: Dextrose 5%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Injection
Description: Dextrose 5%
Study: NCT03961347

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L. johnsonii Probiotic
Description: Participants will consume one capsule of L. johnsonii probiotic daily for 24 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Capsule
Description: Participants will consume one capsule of placebo capsule of dried skim milk daily for 24 weeks.
Study: NCT04281095

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin type A
Description: Total of 20U/0.5mL is intramuscularly administered to five points of the glabellar region, 4U/0.1mL each

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: Total of 20U/0.5mL is intramuscularly administered to five points of the glabellar region, 4U/0.1mL each
Study: NCT00525499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASC-J9 cream
Description: Topical application to the face twice daily for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASC-J9 cream
Description: Topical application to the face twice daily for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASC-J9 cream
Description: Topical application to the face twice daily for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: vehicle control applied topically twice daily for 12 weeks
Study: NCT00535262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EmSam
Description: Selegiline Transdermal System (STS); monoamine oxidase inhibitor patch
Study: NCT02662959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 180 mg/m2, IV (in the vein) on day 1 of each 14 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
Study: NCT05341011

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PEERS® Social Skills Training
Description: The PEERS® consisted of 14 weekly 90-min didactic sessions. Adolescents and their parents attended separate concurrent sessions.~Each session began with a review of the homework assignment from the previous week and allowed time for troubleshooting problems encountered in completing the behavioral assignment. This was followed by a didactic lesson on the weekly topic. Didactic lessons included content related to various social skills and peer interactions. Parents attendance was a mandatory component of PEERS® intervention. Parents were expected to enhance generalization of social skills through in vivo social coaching in natural social settings and increase homework compliance as well as practice of newly learned social skills. A 10-min reunification between adolescents and caregivers was arranged at the end of each session to review the skills taught in the session and assign corresponding homework for the next session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PEERS® Social Skills Training
Description: The PEERS® consisted of 14 weekly 90-min didactic sessions. Adolescents and their parents attended separate concurrent sessions.~Each session began with a review of the homework assignment from the previous week and allowed time for troubleshooting problems encountered in completing the behavioral assignment. This was followed by a didactic lesson on the weekly topic. Didactic lessons included content related to various social skills and peer interactions. Parents attendance was a mandatory component of PEERS® intervention. Parents were expected to enhance generalization of social skills through in vivo social coaching in natural social settings and increase homework compliance as well as practice of newly learned social skills. A 10-min reunification between adolescents and caregivers was arranged at the end of each session to review the skills taught in the session and assign corresponding homework for the next session.
Study: NCT00132808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic Acid
Description: Zoledronic acid 5 mg intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic Acid
Description: Zoledronic acid 5 mg intravenous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Physiologic 0.9% normal saline
Study: NCT00665418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sevoflurane
Description: sevoflurane 2.5% versus 4.7% (inhaled concentration) 10min each
Study: NCT03330340

Intervention type: PROCEDURE
Intervention: Percutaneous Vertebroplasty
Description: The procedure takes place under sterile conditions. Local anesthesia is administered from skin to the periosteum of the targeted pedicle. Polymethylmethacrylate bone cement (Mendec Spine; Tecres SPA, Sommacampagna, Italy) is injected under continuous fluoroscopic imaging guidance using 1.0 ml syringes and 13 Gauge bone biopsy needles by bilateral procedures. The amount of injected cement in each treated vertebral body and any cement leakage is recorded.
Study: NCT00132808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Physiologic 0.9% normal saline
Study: NCT03954418

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Acesulfame K, cyclamate, saccharine, aspartame
Description: Intervention group receives a combination of multiple artificial sweeteners
Study: NCT01999959

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pertubation
Description: a lavage procedure of the intrauterine cavity and bilateral fallopian tubes
Study: NCT03709342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM4620-IE
Description: single IV infusion on Day 1 over 4 hours
Study: NCT01726556

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rigid thoracoscope (Richard Wolf GmbH, Knittlingen, Germany)
Description: Pleuroscopy using a rigid thoracoscope manufactured by Richard Wolf GmbH, Knittlingen, Germany

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Semirigid thoracoscope (model LTF-160Y1, Olympus, Japan)
Description: Pleuroscopy using a semirigid thoracoscope model LTF-160Y1, manufactured by Olympus Medical Systems Corporation, Tokyo, Japan
Study: NCT02451631

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional care with paper
Description: Healthcare staff-driven care, Diabetes mgmt. guide-book provided. Patient self-monitoring of blood glucose(SMBG) with paper.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Health-on G App. + Physician Web
Description: Patients use their smart-phone or receive rental phone, and download Health-On G application. Algorithm-based personalized feedback are provided when patients' data are linked to Health-On G Application. Patient self-monitoring blood glucose data from glucometer are transferred to App. automatically by bluetooth, or input manually, check medication regimen, input food intake and exercise, and step counts are linked by Activity tracker. Personalized feedback are instantly provided based on data. Entered data are also connected to web-based physician portal. Physician web portal is provided, where they're able to review their patient's all data. Health-On G is defined as a U-Healthcare medical device consisting of gateway and decision support system.
Study: NCT02177227

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Attune TruMatch (TM) Patient-Specific Instrumentation
Description: Patients to receive total knee replacement with TruMatch Patient-Specific Instrumentation
Study: NCT02117466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose escalation cetuximab
Description: dose escalation of cetuximab (described in the second arm)

Intervention type: DRUG
Group type: OTHER
Intervention: Standard dose cetuximab
Description: 500mg/m2 bsa cetuximab (described in the first arm)
Study: NCT04564534

Intervention type: OTHER
Intervention: MoCA cognitive assessment
Description: cognitive assessment using the validated MoCA test administered via an application on an iPad
Study: NCT03839316

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: A constant current stimulator (ZMI Electronics LTD.,Taiwan,2012) will be used through 2 saline-soaked surface gel-sponge electrodes (22 cm2 active area). Real stimulation consisting of thirty minutes of 2 mA direct current with the anode placed over the ipsilesional and the cathode over the contralesional motor cortex (C3 and C4 of the international 10-20 EEG electrode system).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tDCS
Description: For sham tDCS, the same electrode positions were used. The current was ramped up to 2 mA and slowly decreased over 30 seconds to ensure the typical initial tingling sensation
Study: NCT01298817

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Medifast meal replacement products
Description: A total of 4 meal replacement (MR)products per participant per day will be used. Approximately 2/3rd of the Medifast® MR product line is soy protein-based (i.e. at least 7 g of total protein coming from soy) with the remaining 1/3rd of items deriving total protein content from animal sources (whey and egg). The soy used in Medifast products is Solae SUPRO® water-washed soy protein isolate. Depending on seasonal variations, soy MR products contain approximately 1.5-3.0 milligrams of soy isoflavones for every 1 gram of soy protein. Thus, participants in the soy treatment arm will consume at least 28 g/soy protein and 42-108 mg/isoflavones per day.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Medifast meal replacement products
Description: A total of 4 meal replacement (MR)products per participant per day will be used. Approximately 2/3rd of the Medifast® MR product line is soy protein-based (i.e. at least 7 g of total protein coming from soy) with the remaining 1/3rd of items deriving total protein content from animal sources (whey and egg). This group will receive the non soy supplements.
Study: NCT00895999

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal Therapy for Pain (IPT-P)
Description: IPT-P focuses on improving relationships as a way to improve depression and pain. The patient and therapist work together to improve communication and enhance relationships and social support. Patients choose a problem focus and goal related to both their pain and depression. Up to 8 IPT-P sessions are provided regardless of ability to pay.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Enhanced Support and Connection to Counseling
Description: Research staff connect patients with the Strong Family Therapy Services, Women's Behavioral Health Service, or other appropriate mental health care and reduce potential barriers from making it to the initial appointment. This support includes navigating insurance issues, addressing issues of childcare and transportation, helping to schedule the initial appointment, reminder calls, and follow-up after the scheduled intake. Research staff will also check-in monthly to see if the patients require any additional support to remain in mental health treatment. Up to 8 therapy sessions are covered regardless of ability to pay.
Study: NCT03914703

Intervention type: PROCEDURE
Intervention: EZ Pass Suture Passer
Description: Instruments used to help with rotator cuff or ACL repair

Intervention type: PROCEDURE
Intervention: EZ Pass Suture Passer
Description: Instruments used to help with rotator cuff or ACL repair
Study: NCT00672490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine Fumarate
Description: Oral treatment, twice daily. 100 mg/day at Day 1, 200 mg/day at Day 2, 300 mg/day at Day 3, 400 mg/day at Day 4, from 400 mg/day to 600 mg/day before Day 8, from 600 mg/day to 800 thereafter, judged by the investigator.~Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine Fumarate
Description: Oral treatment, twice daily. 100 mg/day at Day 1, 200 mg/day at Day 2, 300 mg/day at Day 3, 400 mg/day at Day 4, from 400 mg/day to 600 mg/day before Day 8, from 600 mg/day to 800 thereafter, judged by the investigator.~Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium
Description: Oral treatment, twice daily. 250 mg/day to 2000mg/day from Day1 to Day 7, 500mg/day to 2000mg/day thereafter, judged by the investigator.
Study: NCT03061916

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cinnamon
Description: Cinnamon 20% will be given to participants after baseline collection of saliva

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ginger
Description: Ginger 20% will be given to participants after baseline collection of saliva

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine Gluconate
Description: Chlorhexidine Gluconate will be given to participants after baseline collection of saliva
Study: NCT02141776

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation (t-DCS)
Description: The subjects randomized to this group will receive anodal t-DCS stimulation daily for four weeks. The stimulation parameters: current 2 mA continuously for 30 minutes.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Controlled Arm
Description: The subjects randomized to this group will not receive stimulation daily for four weeks.
Study: NCT01428882

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Midazolam (5 mg/5 mL) 2 mg before standard propofol induction (0.5-1.5 mg/Kg) and boluses-based sedation during colonoscopy, targeted to a moderate sedation level

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propofol
Description: Placebo (normal saline 2 ml) before standard propofol induction (0.5-1.5 mg/Kg) and boluses-based sedation during colonoscopy, targeted to a moderate sedation level
Study: NCT02046551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00368069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Keppra® extended release formulation - XR
Description: 500mg extended release oral tablet, 2 tablets once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral tablets, 2 tablets once daily
Study: NCT02454387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-4474 Part A1
Description: Healthy volunteers

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Part A1
Description: Healthy volunteers

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-4474 Part A2
Description: Healthy volunteers

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Part A2
Description: Healthy volunteers

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-4474 Part B
Description: Healthy volunteers

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Part B
Description: Healthy volunteers

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-4474 Part C
Description: Healthy volunteers

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Part C
Description: Healthy volunteers

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-4474 Part D
Description: Healthy volunteers

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Part D
Description: Healthy volunteers
Study: NCT01660152

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sexual Health Inventory for Men (SHIM) questionnaire administration
Description: Questionnaire will be completed prior to surgery and at 3, 6, 12 months and the compliance questionnaire at 3, 6, 12 months.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sexual Health Inventory for Men (SHIM) questionnaire administration
Description: Questionnaire will be completed prior to surgery and at 3, 6, 12 months and the compliance questionnaire at 3, 6, 12 months.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: management of therapy complications
Description: Receive VED

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: management of therapy complications
Description: Receive VED

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Daily vacuum therapy
Description: Patients randomized to Group A or Group B following removal of catheter at first post op visit following surger. Daily vacuum therapy for approximately 10 minutes. Depending on which group randomized to erection held for 2 minutes or 5 mintues.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Daily vacuum therapy
Description: Patients randomized to Group A or Group B following removal of catheter at first post op visit following surger. Daily vacuum therapy for approximately 10 minutes. Depending on which group randomized to erection held for 2 minutes or 5 mintues.
Study: NCT04123951

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based Exercise
Description: Patients in the home-based exercise arm will complete a 12 week home-based aerobic and resistance exercise training programme. There will be a 2 week period prior to this in which patients will complete up to 6 supervised sessions in order to learn about the home-based exercise training. There will be a 4 week return visit and an optional 8 week return visit in order to reassess fitness and aid the patients with any questions or queries they may have and to aid them in progressing their exercise.
Study: NCT01977651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Participants received 4 capsules (40 mg each) of enzalutamide orally once a day, for a total daily dose of 160 mg. Treatment was given with or without food and as close as possible to the same time each day.